Customs Search

A FUSION PROTEIN ENZYME. USED AS A TARGETED ENZYME REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF HYPOPHOSPHATASIA (HPP) BY NORMALIZING THE GENETICALLY DEFECTIVE METABOLIC PROCESS, AND PREVENTING OR REVERSING THE SEVERE AND LIFE-THREATENING COMPLICATIONS OF LIFE-LONG DYSREGULATED MINERAL METABOLISM. COMPRISED OF THE SOLUBLE CATALYTIC DOMAIN OF HUMAN TISSUE NON-SPECIFIC ALKALINE PHOSPHATE (SALP), THE HUMAN IMMUNOGLOBULIN G1 FC DOMAIN AND OF A DECA ASPARTATE PEPTIDE (D10). IT IS PRODUCED BY MAMMALIAN CELL CULTURE AND PURIFIED BY STANDARD BIOPROCESS TECHNOLOGY. A CLEAR COLOURLESS PRESERVATIVE-FREE SOLUTION AT 100MG/ML OR 40 MG/ML PACKAGED IN 2ML GLASS VIALS (SEVERAL FILL VOLUMES, BUT SAME VIAL). IT IS USED AS A FORMULATED MEDICINAL PRODUCT FOR SUBCUTANEOUS INJECTION. IT IS FORMULATED IN 25MM SODIUM PHOSPHATE, 150 MM SODIUM CHLORIDE AT PH 7.4. THE PREFORMULATED BDS IS SUPPLIED IN A 1L BAG AT A CONCENTRATION OF 100 MG/ML. THE BDS CAN BE FILLED AT THAT CONCENTRATION, OR DILUTED USING THE SAME FORMULATION BUFFER TO 40MG/ML.

A FUSION PROTEIN ENZYME. USED AS A TARGETED ENZYME REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF HYPOPHOSPHATASIA (HPP) BY NORMALIZING THE GENETICALLY DEFECTIVE METABOLIC PROCESS, AND PREVENTING OR REVERSING THE SEVERE AND LIFE-THREATENING COMPLICATIONS OF LIFE-LONG DYSREGULATED MINERAL METABOLISM. COMPRISED OF THE SOLUBLE CATALYTIC DOMAIN OF HUMAN TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (SALP), THE HUMAN IMMUNOGLOBULIN G1 FC DOMAIN AND OF A DECA ASPARTATE PEPTIDE (D10). IT IS PRODUCED BY MAMMALIAN CELL CULTURE AND PURIFIED BY STANDARD BIOPROCESS TECHNOLOGY. A CLEAR COLOURLESS PRESERVATIVE-FREE SOLUTION AT 100MG/ML OR 40 MG/ML PACKAGED IN 2ML GLASS VIALS (SEVERAL FILL VOLUMES, BUT SAME VIAL). IT IS USED AS A FORMULATED MEDICINAL PRODUCT FOR SUBCUTANEOUS INJECTION. IT IS FORMULATED IN 25MM SODIUM PHOSPHATE, 150 MM SODIUM CHLORIDE AT PH 7.4. THE PREFORMULATED BDS IS SUPPLIED IN A 1L BAG AT A CONCENTRATION OF 100 MG/ML. THE BDS CAN BE FILLED AT THAT CONCENTRATION, OR DILUTED USING THE SAME FORMULATION BUFFER TO 40MG/ML. CAS NO. 1174277-80-5

ORENCIA 250MG/15CC VIALS IMPORTED FOR ANALYTICAL TESTING. ORENCIA IS A FINISHED PHARMACEUTICAL PRODUCT. THE ACTIVE INGREDIENT/DRUG SUBSTANCE CONTAINED WITH OTHER EXCIPIENTS IN THE IMPORTED ORENCIA VIAL IS CALLED ABATACEPT (CAS NUMBER 332348-12-6). ABATACEPT IS LISTED IN ANNEX 3 OF THE COMBINED NOMENCLATURE (CN) UNDER CN CODE 3002 10 98

ORENCIA 250MG/15CC VIALS IMPORTED FOR ANALYTICAL TESTING. ORENCIA IS A FINISHED PHARMACEUTICAL PRODUCT. THE ACTIVE INGREDIENT/DRUG SUBSTANCE CONTAINED WITH OTHER EXCIPIENTS IN THE IMPORTED ORENCIA VIAL IS CALLED ABATACEPT (CAS NUMBER 332348-12-6).

A FUSION PROTEIN ENZYME. USED AS A TARGETED ENZYME REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF HYPOPHOSPHATASIA (HPP) BY NORMALIZING THE GENETICALLY DEFECTIVE METABOLIC PROCESS, AND PREVENTING OR REVERSING THE SEVERE AND LIFE-THREATENING COMPLICATIONS OF LIFE-LONG DYSREGULATED MINERAL METABOLISM. COMPRISED OF THE SOLUBLE CATALYTIC DOMAIN OF HUMAN TISSUE NON-SPECIFIC ALKALINE PHOSPHATE (SALP), THE HUMAN IMMUNOGLOBULIN G1 FC DOMAIN AND OF A DECA ASPARTATE PEPTIDE (D10). IT IS PRODUCED BY MAMMALIAN CELL CULTURE AND PURIFIED BY STANDARD BIOPROCESS TECHNOLOGY. A CLEAR COLOURLESS PRESERVATIVE-FREE SOLUTION AT 100MG/ML OR 40 MG/ML PACKAGED IN 2ML GLASS VIALS (SEVERAL FILL VOLUMES, BUT SAME VIAL). IT IS USED AS A FORMULATED MEDICINAL PRODUCT FOR SUBCUTANEOUS INJECTION. IT IS FORMULATED IN 25MM SODIUM PHOSPHATE, 150 MM SODIUM CHLORIDE AT PH 7.4. THE PREFORMULATED BDS IS SUPPLIED IN A 1L BAG AT A CONCENTRATION OF 100 MG/ML. THE BDS CAN BE FILLED AT THAT CONCENTRATION, OR DILUTED USING THE SAME FORMULATION BUFFER TO 40MG/ML.